Pfizer/Boehringer Spiriva For COPD Maintenance Therapy Approved By FDA
Anticipating strong demand for the inhalation therapy, Pfizer and Boehringer are delaying launch until mid-year to ensure sufficient initial supplies of tiotropium bromide.
Anticipating strong demand for the inhalation therapy, Pfizer and Boehringer are delaying launch until mid-year to ensure sufficient initial supplies of tiotropium bromide.